{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T19:21:35Z","timestamp":1791055295724,"version":"4.1.0"},"reference-count":51,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1097\/hjh.0b013e3283649b4d","type":"journal-article","created":{"date-parts":[[2013,9,27]],"date-time":"2013-09-27T22:51:34Z","timestamp":1380322294000},"page":"2290-2299","source":"Crossref","is-referenced-by-count":36,"title":["Effects of telmisartan and linagliptin when used in combination on blood pressure and oxidative stress in rats with 2-kidney-1-clip hypertension"],"prefix":"10.1097","volume":"31","author":[{"given":"Lyubov","family":"Chaykovska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus L.","family":"Alter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karoline","family":"von Websky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarete","family":"Hohmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleg","family":"Tsuprykov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Reichetzeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Kutil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Kraft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berthold","family":"Hocher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-27-20210208","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000339028","article-title":"Renal and cardiac effects of DPP4 inhibitors - from preclinical development to clinical research.","volume":"36","author":"Hocher","year":"2012","journal-title":"Kidney Blood Press Res"},{"key":"R2-27-20210208","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s11906-009-0026-5","article-title":"Update on the metabolic syndrome: hypertension.","volume":"11","author":"Reynolds","year":"2009","journal-title":"Curr Hypertens Rep"},{"key":"R3-27-20210208","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1053\/j.ackd.2010.10.003","article-title":"Hypertension in diabetic nephropathy: epidemiology, mechanisms, and management.","volume":"18","author":"Van Buren","year":"2011","journal-title":"Adv Chronic Kidney Dis"},{"key":"R4-27-20210208","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1080\/080370501750066444","article-title":"The comparative pharmacology of angiotensin II receptor antagonists.","volume":"1","author":"Burnier","year":"2001","journal-title":"Blood Press Suppl"},{"key":"R5-27-20210208","doi-asserted-by":"crossref","first-page":"619","DOI":"10.2353\/ajpath.2010.090578","article-title":"eNOS knockout mice with advanced diabetic nephropathy have less benefit from renin-angiotensin blockade than from aldosterone receptor antagonists.","volume":"176","author":"Kosugi","year":"2010","journal-title":"Am J Pathol"},{"key":"R6-27-20210208","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1161\/HYPERTENSIONAHA.112.195115","article-title":"Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism.","volume":"60","author":"Liu","year":"2012","journal-title":"Hypertension"},{"key":"R7-27-20210208","first-page":"11","article-title":"Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat).","volume":"1-","author":"Ferreira","year":"2010","journal-title":"Mediators Inflamm"},{"key":"R8-27-20210208","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1440-1681.2007.04737.x","article-title":"Effects of dipeptidyl peptidase iv inhibition on arterial blood pressure.","volume":"35","author":"Jackson","year":"2008","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"R9-27-20210208","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1161\/HYPERTENSIONAHA.110.156554","article-title":"Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans.","volume":"56","author":"Marney","year":"2010","journal-title":"Hypertension"},{"key":"R10-27-20210208","doi-asserted-by":"crossref","first-page":"e27861","DOI":"10.1371\/journal.pone.0027861","article-title":"Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy.","volume":"6","author":"Chaykovska","year":"2011","journal-title":"PLoS One"},{"key":"R11-27-20210208","doi-asserted-by":"crossref","first-page":"813","DOI":"10.33549\/physiolres.931581","article-title":"Participation of nitric oxide in different models of experimental hypertension.","volume":"57","author":"Torok","year":"2008","journal-title":"Physiol Res"},{"key":"R12-27-20210208","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000348569","article-title":"Altered activities of antioxidant enzymes in patients with metabolic syndrome.","volume":"6","author":"Vavrova","year":"2013","journal-title":"Obes Facts"},{"key":"R13-27-20210208","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1161\/01.RES.0000099504.30207.F5","article-title":"Contrasting roles of NADPH oxidase isoforms in pressure-overload versus angiotensin II-induced cardiac hypertrophy.","volume":"93","author":"Byrne","year":"2003","journal-title":"Circ Res"},{"key":"R14-27-20210208","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1161\/01.HYP.0000200023.02195.73","article-title":"RNA silencing in vivo reveals role of p22phox in rat angiotensin slow pressor response.","volume":"47","author":"Modlinger","year":"2006","journal-title":"Hypertension"},{"key":"R15-27-20210208","first-page":"455","article-title":"Biomarkers for the prediction of mortality and morbidity in patients with renal replacement therapy.","volume":"57","author":"Chaykovska","year":"2011","journal-title":"Clin Lab"},{"key":"R16-27-20210208","first-page":"6","article-title":"The relationship between reactive oxygen species and cardiac fibrosis in the dahl salt-sensitive rat under ACEI administration.","volume":"1-","author":"Tanaka","year":"2012","journal-title":"Vet Med Int"},{"key":"R17-27-20210208","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1161\/HYPERTENSIONAHA.110.164244","article-title":"Prevention of angiotensin II-mediated renal oxidative stress, inflammation, and fibrosis by angiotensin-converting enzyme 2.","volume":"57","author":"Zhong","year":"2011","journal-title":"Hypertension"},{"issue":"10A","key":"R18-27-20210208","doi-asserted-by":"crossref","first-page":"28G","DOI":"10.1016\/S0002-9149(03)00230-3","article-title":"The ongoing telmisartan alone and in combination with ramipril global endpoint trial program.","volume":"91","author":"Unger","year":"2003","journal-title":"Am J Cardiol"},{"key":"R19-27-20210208","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.lfs.2005.12.036","article-title":"Cardiovascular oxidative stress is reduced by an ACE inhibitor in a rat model of streptozotocin-induced diabetes.","volume":"79","author":"Fiordaliso","year":"2006","journal-title":"Life Sci"},{"key":"R20-27-20210208","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.7150\/ijbs.7.1077","article-title":"Cardioprotective effects of telmisartan against heart failure in rats induced by experimental autoimmune myocarditis through the modulation of angiotensin-converting enzyme-2angiotensin 1-7mas receptor axis.","volume":"7","author":"Sukumaran","year":"2011","journal-title":"Int J Biol Sci"},{"key":"R21-27-20210208","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/labinvest.2011.45","article-title":"Telmisartan, a unique ARB, improves left ventricular remodeling of infarcted heart by activating PPAR gamma.","volume":"91","author":"Maejima","year":"2011","journal-title":"Lab Invest"},{"key":"R22-27-20210208","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1097\/00005344-200406000-00016","article-title":"Candesartan prevents myocardial fibrosis during progression of congestive heart failure.","volume":"43","author":"Onishi","year":"2004","journal-title":"J Cardiovasc Pharmacol"},{"key":"R23-27-20210208","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1084\/jem.59.3.347","article-title":"Studies on experimental hypertension: I. The production of persistent elevation of systolic blood pressure by means of renal ischemia.","volume":"59","author":"Goldblatt","year":"1934","journal-title":"J Exp Med"},{"key":"R24-27-20210208","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1097\/00004872-200018120-00015","article-title":"ETA receptor blockade induces fibrosis of the clipped kidney in two-kidney-one-clip renovascular hypertensive rats.","volume":"18","author":"Hocher","year":"2000","journal-title":"J Hypertens"},{"key":"R25-27-20210208","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1681\/ASN.2006050541","article-title":"Lack of endothelial nitric oxide synthase promotes endothelin-induced hypertension: lessons from endothelin-1 transgenicendothelial nitric oxide synthase knockout mice.","volume":"18","author":"Quaschning","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"R27-27-20210208","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/ki.1986.101","article-title":"Effects of antihypertensive treatment in one-clip, two kidney hypertension in rats.","volume":"29","author":"Michel","year":"1986","journal-title":"Kidney Int"},{"key":"R28-27-20210208","first-page":"F271","article-title":"Blood pressure and renal function during chronic changes in sodium intake: role of angiotensin.","volume":"239","author":"Hall","year":"1980","journal-title":"Am J Physiol"},{"key":"R29-27-20210208","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/sj.ki.5000011","article-title":"Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms.","volume":"69","author":"Huang","year":"2006","journal-title":"Kidney Int"},{"key":"R30-27-20210208","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1124\/jpet.107.126847","article-title":"Inhibition of renal dipeptidyl peptidase IV enhances peptide YY1-36-induced potentiation of angiotensin II-mediated renal vasoconstriction in spontaneously hypertensive rats.","volume":"323","author":"Jackson","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"R31-27-20210208","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1042\/CS20040302","article-title":"Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders.","volume":"108","author":"Gorrell","year":"2005","journal-title":"Clin Sci (Lond)"},{"key":"R32-27-20210208","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1161\/HYPERTENSIONAHA.110.156554","article-title":"Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans.","volume":"56","author":"Marney","year":"2010","journal-title":"Hypertension"},{"key":"R33-27-20210208","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/j.1440-1681.2010.05389.x","article-title":"Sitagliptin augments angiotensin II-induced renal vasoconstriction in kidneys from rats with metabolic syndrome.","volume":"37","author":"Tofovic","year":"2010","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"R34-27-20210208","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0167-0115(99)00031-2","article-title":"Cellular localization, expression and regulation of neuropeptide Y in kidneys of hypertensive rats.","volume":"82","author":"Haefliger","year":"1999","journal-title":"Regul Pept"},{"key":"R35-27-20210208","first-page":"1321","article-title":"Neuropeptide Y modulates the vascular response to periarterial nerve stimulation primarily by a postjunctional action in the isolated perfused rat kidney.","volume":"266","author":"Oellerich","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"R36-27-20210208","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1042\/CS20090047","article-title":"Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition.","volume":"118","author":"Kirby","year":"2009","journal-title":"Clin Sci (Lond)"},{"key":"R37-27-20210208","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1124\/jpet.108.142703","article-title":"Combination of the dipeptidyl peptidase IV inhibitor LAF237 (S)-1-(3-hydroxy-1-adamantyl)ammoacetyl-2-cyanopyrrolidine with the angiotensin II type 1 receptor antagonist valsartan N-(1-oxopentyl)-N-2-(1H-tetrazol-5-yl)-1,1-biphenyl-4-ylmethyl-L-valine enhances pancreatic islet morphology and function in a mouse model of type 2 diabetes.","volume":"327","author":"Cheng","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"R38-27-20210208","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000341487","article-title":"DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy.","volume":"327","author":"Alter","year":"2012","journal-title":"Kidney Blood Press Res"},{"key":"R39-27-20210208","doi-asserted-by":"crossref","first-page":"e41281","DOI":"10.1371\/journal.pone.0041281","article-title":"Chronic kidney disease-induced cardiac fibrosis is ameliorated by reducing circulating levels of a nondialysable uremic toxin, indoxyl sulfate.","volume":"7","author":"Lekawanvijit","year":"2012","journal-title":"PLoS One"},{"key":"R40-27-20210208","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1177\/1074248411434773","article-title":"Ramipril and telmisartan exhibit differential effects in cardiac pressure overload-induced hypertrophy without an additional benefit of the combination of both drugs.","volume":"18","author":"Muller","year":"2013","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"R41-27-20210208","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3810\/pgm.2010.05.2138","article-title":"A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes.","volume":"122","author":"Frederich","year":"2010","journal-title":"Postgrad Med"},{"key":"R42-27-20210208","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1475-2840-11-3","article-title":"Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a prespecified, prospective, and adjudicated meta-analysis of a phase 3 programme.","volume":"11","author":"Johansen","year":"2012","journal-title":"Cardiovasc Diabetol"},{"key":"R44-27-20210208","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.ahj.2011.08.004","article-title":"EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome.","volume":"162","author":"White","year":"2011","journal-title":"Am Heart J"},{"key":"R45-27-20210208","doi-asserted-by":"crossref","first-page":"654","DOI":"10.2337\/diabetes.53.3.654","article-title":"Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects.","volume":"53","author":"Meier","year":"2004","journal-title":"Diabetes"},{"key":"R46-27-20210208","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1081\/CEH-200031904","article-title":"Oxidative stress in hypertension.","volume":"26","author":"de Champlain","year":"2004","journal-title":"Clin Exp Hypertens"},{"key":"R47-27-20210208","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1093\/cvr\/cvs123","article-title":"GLP-1 and cardioprotection: from bench to bedside.","volume":"94","author":"Ravassa","year":"2012","journal-title":"Cardiovasc Res"},{"key":"R48-27-20210208","first-page":"5922","article-title":"DPP-4 inhibition attenuates cardiac dysfunction and adverse remodelling following myocardial infarction in rats with experimental diabetes.","volume":"1755-","author":"Connelly","year":"2012","journal-title":"Cardiovasc Ther"},{"key":"R49-27-20210208","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1161\/CIRCULATIONAHA.107.739938","article-title":"Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways.","volume":"117","author":"Ban","year":"2008","journal-title":"Circulation"},{"key":"R50-27-20210208","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/sj.jhh.1001945","article-title":"Byproducts of oxidative protein damage and antioxidant enzyme activities in plasma of patients with different degrees of essential hypertension.","volume":"20","author":"Simic","year":"2006","journal-title":"J Hum Hypertens"},{"key":"R51-27-20210208","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.yjmcc.2011.08.001","article-title":"Effects of DPP-4 inhibition on cardiac metabolism and function in mice.","volume":"51","author":"Lenski","year":"2011","journal-title":"J Mol Cell Cardiol"},{"key":"R52-27-20210208","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.phrs.2011.02.003","article-title":"Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis.","volume":"63","author":"Matsui","year":"2011","journal-title":"Pharmacol Res"},{"key":"R53-27-20210208","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/cvr\/cvs246","article-title":"Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition.","volume":"96","author":"Kroller-Schon","year":"2012","journal-title":"Cardiovasc Res"}],"container-title":["Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/HJH.0b013e3283649b4d","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T02:03:45Z","timestamp":1646618625000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004872-201311000-00027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":51,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/hjh.0b013e3283649b4d","relation":{},"ISSN":["0263-6352"],"issn-type":[{"value":"0263-6352","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]}}}